reproducibility of plasma nucleosomes and free dna as markers for venous thromboembolism

Conditions: Venous Thromboembolism

Summary: the main objective of this study is to evaluate, for 15 healthy volunteers and for 15 patients with a history of venous thromboembolism (vte), the monthly variation (over 6 months) of plasma nucleosome and free dna concentrations.

the secondary objectives of this study are: a. to describe, for 15 healthy volunteers with no history of venous thromboembolism (vte), plasma nucleosome and dna concentrations. b. to describe, for 100 patients with a history of vte currently consulting for chronic disease or thrombophilia work-up, plasma nucleosome and dna concentrations. c. to compare plasma nucleosome and dna concentrations between healthy volunteers and vte patients d. to describe, for 100 patients with a history of vte currently consulting for chronic disease or thrombophilia work-up, the relationships between classification of vte and plasma nucleosome concentrations: * anatomical classification of vte: (i)superficial, deep ((ii)distal or (iii)proximal), or (iv)pulmonary embolism * circumstantial classification of vte: (i) triggered, no chronic risk factor; (ii) untriggered, with chronic risk factor; (iii)triggered, with chronic risk factor; (iv) untriggered, no chronic risk factor (idiopathic) e. to describe, for 100 patients with a history of vte, the variation in plasma nucleosome concentrations 6 months after the first evaluation * according to the above anatomical classification * according to the above circumstantial classification * according to intercurrent events and treatments f. to compare the plasma concentrations of nucleosomes and free dna g. to evaluate the relationship between plasma nucleosome and free dna concentrations and: * circulating leukocyte populations: total leukocyte count, absolute number of neutrophils, monocytes, lymphocytes * markers of coagulation activation: d-dimers, circulating fibrin monomers * platelet count * patients on antivitamin k: inr, patients receiving heparin: antixa activity h. creation of a biological collection

Eligibility criteria:
inclusion criteria: * the patient or volunteer must have given his/her informed and signed consent * the patient or volunteer must be insured or beneficiary of a health insurance plan * the patient or volunteer is available for 6 months of follow-up for group "p": * patient with a history of vte for group "t": * healthy volunteer * no history of vte * no history of chronic disease * no history of neoplastic disease * no history of chronic infection * not taking anticoagulants, antiplatelet medications * no acute disease or infection during the last 2 weeks exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient is pregnant, parturient, or breastfeeding * the patient gave birth in the past three months

Keywords: nucleosome plasma nucleosome concentrations free dna plasma free dna concentrations